Chelation therapy for autism

EDTA molecule, a chemical chelator responsible for the death of an autistic child from hypocalcemia.

Chelation therapy for autism is a controversial and potentially harmful intervention based on the unproven hypothesis that autism is caused by heavy metal poisoning, particularly from mercury or lead. It is sometimes promoted as a treatment to improve behavior or cure autism, despite the lack of scientific evidence supporting its effectiveness.

Chelation therapy was widely promoted in the United States before 2010 by proponents of the Defeat Autism Now! movement, particularly among holistic practitioners. In 2005, the death of an autistic child undergoing this treatment led the National Institute of Mental Health (NIMH) to suspend a clinical trial for ethical reasons. A 2013 literature review found no evidence supporting the efficacy of chelation for autistic individuals. In France, warnings regarding the use of this treatment began to be issued in 2011.

Chelation therapy is associated with multiple adverse effects, including liver dysfunction, kidney damage, and hypocalcemia. Due to its unfavorable risk–benefit ratio, several health authorities and organizations, including the Cochrane Collaboration, the Haute Autorité de santé (HAS), and the Agence nationale de sécurité du médicament et des produits de santé (ANSM), have issued recommendations against its use in the treatment of autism.